The OncoAlert 🚨 #ESMO24 DAILY Newsletter DAY FOUR OUT TOMORROW MORNING SIGN UP TO RECEIVE IT Oncoalert360.com or oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅ROME ✅GigaPATH🔬 ✅NO-CUT ✅PIONEER ✅AMG193 ✅TOPGEAR ⚙️(NEJM) ✅DESTINY Breast06 (NEJM) ✅CABINET 🗄️(NEJM)

Dear ESMO - Eur. Oncology Thank you for a Great #ESMO24 Dear Colleagues Thank You for your Support🌐 We Are OncoAlert 🚨 See you in Berlin 🇩🇪 Anirban Maitra Pashtoon Kasi MD, MS Dr. Cathy Eng Mark Lewis, MD, FASCO Andres Cervantes Manju George MVSc PhD Rectal Cancer Survivor Stacy Hurt (she/her)🌻 Allison Rosen, MS Kohei shitara Sharlene Gill, MD, MPH, MBA, FASCO Ben Westphalen

Dear ESMO - Eur. Oncology Thank you for a Great #ESMO24 Dear Colleagues Thank You for your Support🌐 We Are OncoAlert 🚨 See you in Berlin 🇩🇪 Don S. Dizon MD (he/him) 🇬🇺 Merry-Jennifer Markham, MD, FACP, FASCO Ane Gerda Z Eriksson MD PhD Dee Sparacio Meredith GTrinidad, MD Sandip Patel MD Wafik S. El-Deiry, MD, PhD, FACP Charles Swanton Vivek Subbiah, MD John Haanen Julie Gralow

THE OncoAlert 🚨Complete #ESMO24 Newsletter OUR PICKS TOP TRIALS Out of the Entire Congress SIGN UP TO RECEIVE IT Oncoalert360.com or oncoalert.m-pages.com/nhMpwe/oncoale… gilberto lopes Narjust Florez, MD, FASCO Stephen V Liu, MD Sébastien Couraud 🫁🚭🌍 Jill Feldman Sanjay Popat Matteo Lambertini, MD PhD

Dear Colleagues, OncoAlert 🚨is honoured to be covering #PROSCA24 #BLADDR24 & #RENALC24 by Mirrors of Medicine for the Second Year REGISTER: mirrorsofmedicine.idloom.events/RenalcBladdrPr… This November 26-30, 2024 in Vienna Austria, 3 great back to back meetings on How New GU Data is Translated into

Barcelona 🇪🇸 #ESMO24 Thank You!! For Colleagues....By Colleagues We Are ALL OncoAlert #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Biagio Ricciuti, MD PhD Emre Yekedüz Hidehito HORINOUCHI Fadi Haddad, MD Dr. Iván R. González Al-Ola A Abdallah MD (USMIRC) Jose Fernando Moura, PhD Elisa Agostinetto Elisabetta Bonzano MD, PhD

Dear Colleagues at #ESMO24 Do not miss EVERY MORNING The #OncoAlertTOPTweet 🚨 Giving you the TOP 10-15 posts of the Day before.. Perfect for those on the GO! OncoAlert360.com #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Biagio Ricciuti, MD PhD Emre Yekedüz

Dear Colleagues Thank you for a great #ESMO24 !! Visit VJ Oncology for independent, Open-Access medical News and Education by Top Experts Worldwide who give you a run down out of all the great science out of Barcelona. Visit at: bit.ly/3MrFWEc

The OncoAlert 🚨Network Proudly announces 5 NEW Catalyst Fellowships, exclusively for Oncologists working in LMIC's wanted to do research with The Network...APPLY NOW!!! oncoalert360.com/the-catalyst-f… Our Gratitude to the good people at Bayer forsupporting these 5 Fellowships!!

How is Clinical Practice Changing in Advanced #ProstateCancer Post #ESMO24 ?? Mirrors of Medicine invites you to a discussion around PEACE III with Fred Saad and tombal Wednesday October 2, 7pm CEST Registration Link: us02web.zoom.us/webinar/regist…

Which one was your favorite #ESMO2024 Presidential Symposium? ESMO - Eur. Oncology FabriceAndre OncoAlert Andres Cervantes Myriam Chalabi Rebecca Dent

its not just where we have been & where we are .....it's where WE ARE GOING🌐 We Are ALL OncoAlert 🚨

EVERGREEN study led by Diogo Martins Branco A quasi-experimental analysis of >200 pts, showed that Everolimus+ET ⬆️ PFS (aHR 0.68, CI 0.47-0.99) vs ET alone after progression on CDK4/6i EVE had higher efficacy when combined with AI, ⬆️ BMI, IDC, and longer prior CDK4/6 Tx OncoAlert

Proud to be part of this large global study on young BRCA carriers with breast cancer Lobular tumors ⬆️ grade 1/2 (58% vs. 22%), stage III (30% vs. 18%), and luminal A-like (42% vs. 12%), and linked to BRCA2 (71%) No sig diff in DFS or OS compared to IDC OncoAlert

Beyond Proud of our Friend and @oncoalert 🚨Faculty Toni Choueiri, MD , Great choice ESMO - Eur. Oncology #ESMO25

A short but wonderful #ESMO24 — came for the science that will absolutely change our practice and patient outcomes, stayed for the many connections w colleagues across academics, industry, & education forums! Thanks ESMO - Eur. Oncology!! Honored to have been one of the #ESMOAmbassadors

Novartis today announced that the FDA has approved ribociclib in combination with an AI for the adjuvant treatment of HR+/HER2-neg stage II-III EBC based on the results of NATALEE presented at #ESMO24 OncoAlert novartis.com/news/media-rel…

#Ribociclib now U.S. FDA ✅ for adj early stage HR+ breast cancer. Recent #ESMO24 #NATALEE: Stg IIA - III, 400mg (3wks on/1wk off) for 3yrs - Improved iDFS w/Ribo at 4yrs (HR: 0.715) - Improvement seen in all subgroups including N0. OS immature #bcsm #OncTwitter OncoAlert

📌 FDA approves ribociclib with an aromatase inhibitor and ribociclib and letrozole co-pack for early high-risk breast cancer ✅ OncoAlert #OncoAlertAF fda.gov/drugs/resource…

The U.S. FDA 🇺🇸approved ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive,🧬HER2-negative stage II and III early breast cancer at high risk of recurrence. The approval was based on the NATALEE trial,